Keytruda Price Per Infusion in USA | Updated 2025 Guide

Keytruda Price Per Infusion in USA | Updated 2025 Guide

Pembrolizumab (Keytruda) — everything you need to know about cost, insurance, savings, and what you might pay in 2025

1. What is Keytruda?

  • Generic name: pembrolizumab

  • Type: Immune checkpoint inhibitor (anti-PD-1 antibody)

  • Indications: Lung cancer, melanoma, head & neck cancers, colorectal cancer, and more

  • Administration: Intravenous infusion (~30 minutes) at doses of 200 mg every 3 weeks or 400 mg every 6 weeks.

📖 Official FDA drug information


2. Keytruda’s List Price per Infusion (USA 2025)

Dose / Schedule Price per Infusion (List / ASP)
200 mg every 3 weeks ≈ US$11,564.16 (Medical News Today)
400 mg every 6 weeks ≈ US$23,590.88 (Keytruda official site)

💡 According to CMS (Medicare ASP Pricing Data), the average sales price (ASP) in July–Sept 2025 is ~$58.56 per mg, giving ~$11,712.40 per 200 mg infusion.

⚠️ Note: List price ≠ what patients pay. Insurance and assistance programs significantly reduce out-of-pocket costs.


3. What Patients Actually Pay (Out-of-Pocket)

Your real cost depends on insurance and eligibility:

  • Commercial insurance: $0 – $375 per infusion (Merck Co-pay Assistance)

  • Medicare Advantage: $0 – $1,325 per infusion

  • Traditional Medicare (no Medigap): $1,300 – $2,100 per infusion (Drugs.com Medicare Coverage)

  • Medicaid: $4 – $8 per infusion, depending on state (Medicaid.gov)

📊 A Serif Health Transparency Study shows commercial insurers sometimes pay $12,000–$30,000+ depending on provider & location.


4. Factors That Affect Keytruda Pricing

  • Dosage & frequency: FDA dosing guide

  • Hospital vs outpatient clinic: Hospitals often add facility fees

  • Insurance plan design: Deductibles, coinsurance, out-of-network charges

  • Additional medical costs: Labs, infusion fees, monitoring

  • Regional variation: Negotiated prices differ by state/provider


5. Insurance, Medicare & Medicaid Coverage

  • Medicare Part B: Covers Keytruda for approved cancer indications. Patients usually pay 20% coinsurance unless they have Medigap (Medicare.gov).

  • Medicare Advantage (Part C): Out-of-pocket costs vary by plan formulary.

  • Medigap: Helps reduce coinsurance or deductible burdens.

  • Medicaid: Often the most affordable, sometimes as low as $4 per dose (Medicaid pharmacy benefits).


6. Financial Assistance & Savings Programs

  • Merck Access Program – support for uninsured/underinsured patients

  • Merck Co-pay Assistance – eligible patients may pay as little as $25 per infusion

  • GoodRx Keytruda pricing tool

  • HealthWell Foundation – nonprofit support for cancer patients


7. New Developments (2025)

  • Subcutaneous Keytruda: Merck plans U.S. launch in October 2025, making administration faster (Reuters).

  • Drug price negotiations: Starting 2026, Keytruda will be part of the Inflation Reduction Act’s Medicare drug price negotiations, potentially lowering costs by 2028 (Reuters).


8. Frequently Asked Questions (FAQs)

Q1: Is there a generic Keytruda?
A: No. There are currently no FDA-approved biosimilars for pembrolizumab (FDA biosimilars info).

Q2: How much does Keytruda cost with Medicare?
A: About $11,500 list price per 200 mg infusion, but patients typically pay $1,300–$2,100 depending on plan coverage (Medical News Today).

Q3: What if I have no insurance?
A: Expect full list price ($11,000–$23,000+ per infusion) unless you qualify for Merck’s patient assistance.

Q4: Does Medicaid cover Keytruda?
A: Yes, at very low out-of-pocket cost (usually $4–$8) depending on state (Medicaid state profiles).

Q5: How long will I need Keytruda?
A: Treatment duration varies; many patients receive infusions for up to 2 years, depending on cancer type and response.


9. High-Value SEO Keywords

  • Keytruda cost per infusion 2025

  • Keytruda price USA insurance

  • Pembrolizumab price guide

  • Keytruda Medicare coverage cost

  • Keytruda co-pay assistance 2025

  • Immunotherapy cancer drug cost


10. Conclusion

Keytruda is a groundbreaking treatment for many cancers but comes with very high costs in the USA—$11,000+ per infusion at list price.

✅ The good news: most patients do not pay full price. With insurance, Medicare/Medicaid, co-pay support, and nonprofit aid, many can access treatment at significantly lower out-of-pocket cost.

📌 If you or a loved one is prescribed Keytruda:

  • Talk to your oncologist about insurance coverage

  • Ask your provider to check Merck Access Programs

  • Compare state Medicaid options

  • Stay updated about 2025–2028 pricing changes


References

Additional Images

Related Articles

Keytruda Cost in the USA: How Much Does Pembrolizumab Really Cost in 2025?

Keytruda Cost in the USA: How Much Does Pembrolizumab Really Cost in 2025?

2025-09-09 | 384 views

Keytruda (pembrolizumab) is one of the most widely used immunotherapy drugs for treating different types of cancer, including lung cancer, melanoma, and head and neck cancers. In the United States, the cost of Keytruda can be a major concern for patients and their families, as it is often priced at several thousand dollars per infusion. This article explores the average cost of Keytruda in the USA, insurance coverage options, financial assistance programs, and helpful resources for patients seeking more affordable access.

How Much Does Opdivo Cost in the USA? | Nivolumab Price 2025

How Much Does Opdivo Cost in the USA? | Nivolumab Price 2025

2025-09-11 | 175 views

In 2025, the cost of Opdivo (nivolumab) in the United States remains a major concern for cancer patients and caregivers. With list prices starting at around $7,600 per infusion and reaching over $36,000 per vial, understanding insurance coverage, financial assistance programs, and the newly approved subcutaneous form (Opdivo Qvantig) is essential. This guide explains the latest prices, cost-saving options, and answers the most common questions about Opdivo treatment in the U.S.

How Much Does Keytruda Cost Per Month?

How Much Does Keytruda Cost Per Month?

2025-09-12 | 156 views

Keytruda (pembrolizumab) has transformed cancer treatment, but its price tag remains one of the highest in oncology. In 2025, the average monthly cost of Keytruda in the United States is estimated at $15,000 to $16,000, depending on the dosing schedule. While list prices are staggering, most patients do not pay this full amount thanks to insurance coverage, Medicare benefits, and financial assistance programs. Still, questions like “How much does Keytruda cost per month?” and “Why is Keytruda so expensive?” are critical for patients, caregivers, and policymakers navigating the realities of modern cancer care.

Comments (0)

No comments yet. Be the first to comment!

Add a Comment